Glutaminyl Cyclase, Diseases, and Development of Glutaminyl

An overview of glutaminyl cyclase inhibitors for Alzheimer's disease

Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design - ScienceDirect

IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminyl cyclase isoenzymes

Upregulation of Glutaminyl Cyclase Contributes to ERS-Induced Apoptosis in PC12 Cells

Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases - ScienceDirect

Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation

Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease - ScienceDirect

Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions - ScienceDirect

Frontiers Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease